Tarsus Pharmaceuticals In...

NASDAQ: TARS · Real-Time Price · USD
54.99
0.85 (1.57%)
At close: Aug 15, 2025, 12:41 PM

Tarsus Pharmaceuticals Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
102.66M 78.33M 66.41M 48.12M 40.81M 27.61M 13.08M 1.87M n/a 2.5M 10M n/a 15.28M 539K 338K 1.24M 22.02M 33.43M
Cost of Revenue
6.24M 5.21M 4.93M 3.24M 3M 1.65M 1.22M 377K n/a 255K 400K 10.91M 522K 33K 8.01M 65K 737K 1.3M
Gross Profit
96.42M 73.12M 61.48M 44.88M 37.81M 25.96M 11.86M 1.49M n/a 2.25M 9.6M -10.91M 14.76M 506K -7.68M 1.18M 21.28M 32.13M
Operating Income
-22.18M -26.28M -24.42M -25.16M -33.3M -37.68M -44.45M -40.94M -32.82M -24.95M -15.06M -22.91M -5.22M -19.52M -14.45M -15.71M 7.28M 10.71M
Interest Income
4.23M 3.45M 3.65M 4.12M 4.13M 3.12M 2.98M 2.84M 2.23M 2.29M 2.13M 1.06M 297K n/a 36.00 8K n/a n/a
Pretax Income
-20.34M -25.12M -23.11M -23.42M -33.29M -35.73M -41.9M -40.94M -31.42M -23.42M -13.6M -22.52M -5.74M -20.24M -14.8M -16.04M 6.37M 10.69M
Net Income
-20.34M -25.12M -23.11M -23.42M -33.29M -35.73M -41.9M -39.15M -31.42M -21.89M -13.08M -22.51M -5.74M -20.24M -14.85M -15.7M 6.34M 10.38M
Selling & General & Admin
103.01M 85M 69.03M 57.91M 58.79M 51.58M 43.01M 30.32M 20.27M 15.1M 14.63M 11.99M 10.38M 7.95M 6.77M 6.67M 6.79M 5.16M
Research & Development
15.59M 14.41M 16.87M 12.13M 12.32M 12.07M 13.3M 12.11M 12.55M 12.36M 10.03M 10.91M 9.6M 12.08M 8.04M 10.21M 7.2M 16.26M
Other Expenses
n/a n/a n/a n/a n/a 605K -13K -48K n/a 6K -50K -7K n/a 37K -5K 5K -39K -34K
Operating Expenses
118.61M 99.4M 85.9M 70.04M 71.11M 63.64M 56.31M 42.43M 32.82M 27.45M 24.66M 22.91M 19.98M 20.03M 14.81M 16.88M 14M 21.42M
Interest Expense
2.24M 2.21M 2.31M 2.44M 2.11M 983K 989K 858K 815K 684K 692K 633K 544K 316K n/a n/a 7K 9K
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a -22.69M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
124.84M 104.61M 90.83M 73.28M 74.11M 65.3M 57.53M 42.81M 32.82M 27.45M 25.06M 22.91M 20.5M 20.06M 14.79M 16.95M 14.73M 22.72M
Income Tax Expense
n/a n/a n/a n/a n/a -270K n/a -1.79M n/a -1.53M -521K -5K n/a 1K 54K -341K 29K 313K
Shares Outstanding (Basic)
42.36M 39.35M 38.56M 38.38M 37.82M 35.3M 31.94M 30.62M 26.82M 26.74M 26.73M 26.66M 24.33M 20.65M 20.56M 20.64M 20.56M 20.34M
Shares Outstanding (Diluted)
42.36M 39.35M 38.56M 38.38M 37.82M 35.3M 31.94M 30.62M 26.82M 26.74M 26.73M 26.66M 24.33M 20.71M 20.64M 20.64M 21.97M 21.82M
EPS (Basic)
-0.48 -0.64 -0.61 -0.61 -0.88 -1.01 -1.31 -1.28 -1.17 -0.82 -0.49 -0.84 -0.24 -0.98 -0.72 -0.76 0.31 0.51
EPS (Diluted)
-0.48 -0.64 -0.61 -0.61 -0.88 -1.01 -1.31 -1.28 -1.17 -0.82 -0.49 -0.84 -0.24 -0.98 -0.72 -0.76 0.29 0.47
EBITDA
-17.65M -26.28M -20.37M -20.68M -30.94M -34.48M -40.57M -37.92M -30.43M -22.48M -12.69M -21.67M -5.11M -19.77M -14.41M -15.86M 7.41M 10.78M
EBIT
-18.1M -27.33M -20.8M -21.1M -31.18M -34.78M -40.94M -38.32M -30.61M -22.73M -12.91M -21.93M -5.2M -19.92M -14.45M -16.04M 6.37M 10.69M
Depreciation & Amortization
453K 1.05M 432K 284K 239K 270K 347K 369K 182K 255K 219K 94K 92K 478K 40K 83K 125K 64K